基金項(xiàng)目:隨州市衛(wèi)生和計(jì)劃生育委員會(huì)資助項(xiàng)目(2018SZ32008)
作者單位:隨州市中心醫(yī)院婦產(chǎn)科(郵編441300)
作者簡(jiǎn)介:蔣韜(1985),女,主治醫(yī)師,主要從事高危妊娠方面研究。E-mail:muuuuuv@163.com
△通信作者 E-mail:qmrdcztchao3@163.com
摘要:目的 探討棕矢車菊素對(duì)妊娠糖尿?。℅DM)大鼠炎癥反應(yīng)的影響及可能機(jī)制。方法 將妊娠大鼠腹腔注射鏈脲佐菌素建立GDM模型,將建模成功大鼠分為GDM組,棕矢車菊素-L、M、H組,棕矢車菊素+CTCE-0214[基質(zhì)細(xì)胞衍生因子1α(SDF-1α)/趨化因子受體4(CXCR4)激活劑]組,每組10只;另取10只健康妊娠大鼠作為對(duì)照組。棕矢車菊素-L、M、H組分別灌胃2、3、4 mg/kg棕矢車菊素,棕矢車菊素+CTCE-0214組腹腔注射10 mg/kg CTCE-0214并灌胃4 mg/kg棕矢車菊素,對(duì)照組和GDM組給予等量生理鹽水。比較各組大鼠空腹血糖、空腹胰島素以及胰島素抵抗指數(shù)差異;酶聯(lián)免疫吸附測(cè)定法檢測(cè)大鼠胎盤組織中白細(xì)胞介素(IL)-1β、腫瘤壞死因子(TNF)-α水平;HE染色觀察胎盤組織病理變化;TUNEL檢測(cè)胎盤組織細(xì)胞凋亡;Western blot檢測(cè)大鼠胎盤組織中SDF-1α/CXCR4通路相關(guān)蛋白水平。結(jié)果 不同劑量棕矢車菊素干預(yù)GDM大鼠引起大鼠空腹血糖、空腹胰島素、胰島素抵抗指數(shù)水平降低,促炎細(xì)胞因子水平降低,改善GDM大鼠胎盤損傷和細(xì)胞凋亡,并抑制SDF-1α/CXCR4信號(hào)通路激活,呈劑量依賴性(P<0.05),SDF-1α/CXCR4激活劑和棕矢車菊素聯(lián)合干預(yù)后抑制棕矢車菊素上述作用。結(jié)論 棕矢車菊素可通過抑制SDF-1α/CXCR4信號(hào)通路激活來(lái)減輕GDM大鼠炎癥反應(yīng)和胰島素抵抗。
關(guān)鍵詞:糖尿病,妊娠;疾病模型,動(dòng)物;趨化因子CXCL12;炎癥;棕矢車菊素;趨化因子配體4
中圖分類號(hào):R587.1,R714.256 文獻(xiàn)標(biāo)志碼:A DOI:10.11958/20231228
Effect of Jaceosidin on inflammatory response in gestational diabetes mellitus rats by regulating SDF-1α/CXCR4 signaling pathway
JIANG Tao, CHENG Hongyan, WU Qiong△
Department of Obstetrics and Gynecology, Suizhou Central Hospital, Suizhou 441300, China
△Corresponding Author E-mail: qmrdcztchao3@163.com
Abstract: Objective To investigate the effect of Jaceosidin on inflammatory response in gestational diabetes mellitus (GDM) rats and its mechanism. Methods The GDM rat model was established by intraperitoneal injection of streptozotocin into pregnant rats. The successfully established rats were separated into the GDM group, the Jaceosidin L, M, H groups and the Jaceosidin+CTCE-0214 [stromal cell-derived factor-1α (SDF-1α)/C-X-C chemokine receptor 4 (CXCR4) activator] group, with 10 rats in each group. Meantime, 10 healthy pregnant rats were taken as the control group. The Jaceosidin L, M and H groups were gavaged with 2, 3 and 4 mg/kg Jaceosidin, respectively. The Jaceosidin+CTCE-0214 group was intraperitoneally injected with 10 mg/kg CTCE-0214 and gavaged with 4 mg/kg Jaceosidin. The control group and the GDM group were given equal amounts of physiological saline. The fasting blood glucose, fasting insulin and insulin resistance index were compared between each group of rats. Enzyme-linked immunosorbent assay was applied to detect levels of IL-1β and TNF-α in placental tissue. HE staining was applied to observe pathological changes of placental tissue. Apoptosis of placental tissue was detected by TUNEL. Western blot assay was applied to detect levels of SDF-1α/CXCR4 pathway related proteins in placental tissue. Results The intervention of different doses of Jaceosidin in GDM rats reduced levels of fasting blood glucose, fasting insulin, insulin resistance index and proinflammatory cytokines, improved the placental injury and apoptosis of GDM rats, and inhibited the activation of SDF-1α/CXCR4 signaling pathway in a dose-dependent manner (P<0.05). SDF-1α/CXCR4 activator combined Jaceosidin could inhibit the above effects of Jaceosidin. Conclusion Jaceosidin can reduce inflammation and insulin resistance in GDM rats by suppressing the activation of SDF-1 α/CXCR4 signaling pathway.
Key words: diabetes, gestational; disease models, animal; chemokine CXCL12; inflammation; Jaceosidin; chemokine ligand 4
妊娠期糖尿?。╣estational diabetes mellitus,GDM)是常見的妊娠并發(fā)癥之一,在全球范圍內(nèi)患病率呈上升趨勢(shì)[1-2]。炎癥是促進(jìn)胰島素抵抗的關(guān)鍵因素[3]。懷孕期間,由于胎盤催乳素和其他激素的變化,母體組織對(duì)胰島素變得不敏感。對(duì)于患有GDM的女性,胰島素抵抗會(huì)導(dǎo)致母體高血糖并刺激胎兒發(fā)生高胰島素血癥[4]。因此,抑制GDM引起的炎癥反應(yīng),從而抑制胰島素抵抗,對(duì)GDM治療至關(guān)重要。基質(zhì)細(xì)胞衍生因子1(stromal cell-derived factor 1α,SDF-1α)/趨化因子受體4(C-X-C chemokine receptor 4,CXCR4)通路可以趨化機(jī)體炎癥細(xì)胞,發(fā)揮促進(jìn)炎癥作用[5]。研究發(fā)現(xiàn),抑制SDF-1α/CXCR4通路會(huì)改變糖尿病小鼠的病程進(jìn)展,抑制胰島炎癥,表明SDF-1α/CXCR4通路活化促進(jìn)炎癥反應(yīng)且參與糖尿病發(fā)展[6]。棕矢車菊素(Jaceosidin)是一種黃酮類化合物,主要存在于艾葉、野馬追中,具有抗氧化、抗炎、抗過敏等多種功效[7]。棕矢車菊素能夠降低2型糖尿病小鼠空腹血糖水平以及胰島素抵抗[8];在1型糖尿病小鼠中棕矢車菊素可發(fā)揮降糖作用[9]。因此,棕矢車菊素有望成為治療胰島素抵抗以及糖尿病相關(guān)疾病的潛在候選藥物。本研究旨在探究棕矢車菊素在GDM中的作用,并分析其潛在機(jī)制。
1 材料與方法
1.1 材料 2月齡SPF級(jí)雌性SD大鼠80只和雄性SD大鼠40只,體質(zhì)量220~240 g,購(gòu)自華中科技大學(xué)動(dòng)物實(shí)驗(yàn)中心,生產(chǎn)許可證號(hào):SCXK(鄂)2021—0009,本實(shí)驗(yàn)經(jīng)本院動(dòng)物倫理委員會(huì)批準(zhǔn)(批準(zhǔn)號(hào)20220301)。棕矢車菊素、SDF-1α/CXCR4激活劑CTCE-0214(美國(guó)MCE公司);胰島素、白細(xì)胞介素(IL)-1β、腫瘤壞死因子(TNF)-α酶聯(lián)免疫吸附試驗(yàn)(ELLSA)試劑盒(北京索萊寶生物科技有限公司);蘇木精-伊紅(HE)染色液、原位末端標(biāo)記(TdT-mediated dUTP nick-end labeling,TUNEL)凋亡檢測(cè)試劑盒(上海碧云天生物科技有限公司);兔源SDF-1α、CXCR4、β-肌動(dòng)蛋白(β-actin)一抗抗體和辣根過氧化物酶標(biāo)記的山羊抗兔IgG二抗(美國(guó)CST公司)。血糖儀(羅氏血糖健康醫(yī)護(hù)公司);Epoch全波長(zhǎng)酶標(biāo)儀(美國(guó)BioTek公司);BX53熒光顯微鏡(日本Olympus公司)。
1.2 研究方法
1.2.1 疾病模型制作和分組 大鼠適應(yīng)性飼喂7 d,高脂飼料飼喂2個(gè)月后按照雌∶雄=2∶1將大鼠混養(yǎng),次日使用陰道涂片鏡觀察大鼠受孕情況,挑選60只成功受孕的妊娠大鼠腹腔注射STZ 60 mg/kg,72 h后檢測(cè)空腹血糖gt;12 mmol/L,并且大鼠出現(xiàn)多飲、多食以及多尿則造模成功[10]。隨機(jī)抽取50只造模成功大鼠分為GDM組和棕矢車菊素-L、M、H組,棕矢車菊素+CTCE-0214(SDF-1α/CXCR4激活劑)組,每組10只。另取10只健康妊娠大鼠作為對(duì)照組。棕矢車菊素-L、M、H組分別灌胃2、3、4 mg/kg棕矢車菊素[11]。棕矢車菊素+ CTCE-0214組腹腔注射10 mg/kg CTCE-0214[12]并且灌胃4 mg/kg棕矢車菊素。對(duì)照組和GDM組注射以及灌胃等量生理鹽水。1次/d,連續(xù)給藥14 d。
1.2.2 各組大鼠空腹血糖、空腹胰島素以及胰島素抵抗指數(shù)檢測(cè) 末次給藥結(jié)束后,各組大鼠均禁食12 h,剪尾采血0.3 mL,血糖儀測(cè)量空腹血糖水平。戊巴比妥鈉腹腔注射麻醉大鼠,取腹主動(dòng)脈血3 mL,1 200×g、4 ℃離心5 min分離血清,ELISA試劑盒檢測(cè)各組大鼠空腹胰島素水平,計(jì)算胰島素抵抗指數(shù)=空腹血糖×空腹胰島素/22.5。
1.2.3 ELISA法檢測(cè)大鼠胎盤組織中IL-1β、TNF-α表達(dá)水平 取血完成后處死大鼠,分離并解剖子宮,取大鼠胎盤組織,將部分胎盤組織剪碎,加入預(yù)冷磷酸鹽緩沖液(phosphate buffered saline,PBS)研磨,1 200×g、4 ℃離心20 min獲得上清液,ELISA試劑盒檢測(cè)IL-1β、TNF-α水平。
1.2.4 HE染色觀察胎盤組織病理變化 取部分胎盤組織,4%甲醛固定后,石蠟包埋,切片行HE染色,光鏡下觀察胎盤組織病理變化。
1.2.5 TUNEL檢測(cè)胎盤組織細(xì)胞凋亡 取石蠟包埋胎盤組織切片,用TUNEL試劑盒染色,DAPI染核,熒光顯微鏡下觀察凋亡細(xì)胞數(shù),計(jì)算TUNEL陽(yáng)性細(xì)胞百分比即細(xì)胞凋亡率。
1.2.6 Western blot檢測(cè)大鼠胎盤組織中SDF-1α/CXCR4通路相關(guān)蛋白表達(dá) 將部分胎盤組織在冰冷的裂解緩沖液中勻漿。冰上勻漿后,將組織勻漿液離心,采用BCA法測(cè)定總蛋白濃度。每個(gè)泳道中加入等量的變性蛋白質(zhì),將蛋白質(zhì)進(jìn)行SDS-PAGE電泳并轉(zhuǎn)移到PVDF膜上,與相應(yīng)一抗SDF-1α(1∶1 000)、CXCR4(1∶1 000)、β-actin(1∶2 000)4 ℃孵育過夜,二抗(1∶2 000)室溫孵育1 h后,膜在PBS中洗滌3次,每次10 min,使用增強(qiáng)化學(xué)熒光試劑檢測(cè)目標(biāo)蛋白,通過Image J對(duì)條帶進(jìn)行量化。
1.3 統(tǒng)計(jì)學(xué)方法 采用GraphPad Prism 7.0軟件進(jìn)行數(shù)據(jù)分析。計(jì)量資料以[x] ±s表示,多組間比較采用單因素方差分析,組間多重比較Tukey檢驗(yàn),P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 各組大鼠糖代謝情況 與對(duì)照組相比,GDM組大鼠空腹血糖、空腹胰島素、胰島素抵抗指數(shù)升高(P<0.05);與GDM組相比,棕矢車菊素-L、M、H組大鼠的空腹血糖、空腹胰島素、胰島素抵抗指數(shù)水平依次降低(P<0.05);與棕矢車菊素-H組相比,棕矢車菊素+CTCE-0214組大鼠空腹血糖、空腹胰島素、胰島素抵抗指數(shù)水平升高(P<0.05),見表1。
2.2 各組大鼠胎盤組織中IL-1β、TNF-α水平比較 與對(duì)照組相比,GDM組大鼠胎盤組織中IL-1β、TNF-α水平升高(P<0.05);與GDM組相比,棕矢車菊素-L、M、H組大鼠胎盤組織中IL-1β、TNF-α水平依次降低(P<0.05);與棕矢車菊素-H組相比,棕矢車菊素+CTCE-0214組大鼠胎盤組織中IL-1β、TNF-α水平升高(P<0.05),見表2。
2.3 各組大鼠胎盤組織病理變化比較 對(duì)照組大鼠胎盤組織細(xì)胞均勻分布,毛細(xì)血管分布均勻;GDM組大鼠胎盤組織嚴(yán)重?fù)p傷,細(xì)胞分布混亂,毛細(xì)血管減少,細(xì)胞間隙變大;棕矢車菊素-L、M、H組大鼠胎盤組織損傷逐漸減小,細(xì)胞逐漸排列有序,毛細(xì)血管增多;棕矢車菊素+CTCE-0214組棕矢車菊素保護(hù)作用被抑制,損傷加重,見圖1。
2.4 各組大鼠胎盤組織細(xì)胞凋亡情況比較 與對(duì)照組相比,GDM組大鼠胎盤組織凋亡率升高(P<0.05);與GDM組相比,棕矢車菊素-L、M、H組大鼠胎盤組織凋亡率依次降低(P<0.05);與棕矢車菊素-H組相比,棕矢車菊素+CTCE-0214組大鼠胎盤組織凋亡率升高(P<0.05),見表2、圖2。
2.5 各組大鼠胎盤組織中SDF-1α/CXCR4通路相關(guān)蛋白水平比較 與對(duì)照組相比,GDM組大鼠胎盤組織SDF-1α、CXCR4蛋白水平升高(P<0.05);與GDM組相比,棕矢車菊素-L、M、H組大鼠胎盤組織SDF-1α、CXCR4蛋白水平依次降低(P<0.05);與棕矢車菊素-H組相比,棕矢車菊素+CTCE-0214組大鼠胎盤組織SDF-1α、CXCR4蛋白水平升高(P<0.05),見圖3、表3。
3 討論
GDM是一種常見的內(nèi)分泌代謝疾病,妊娠期出現(xiàn)不同程度的糖脂代謝紊亂,給母親和胎兒帶來(lái)危險(xiǎn),甚至危及生命,其重要病理特征為胰島素抵抗[13]。在正常妊娠過程中,適當(dāng)胰島素抵抗的生理狀態(tài)可優(yōu)先將母體營(yíng)養(yǎng)物質(zhì)引導(dǎo)至胎盤軸,促進(jìn)胎兒生長(zhǎng)[14]。但當(dāng)母體發(fā)生GDM時(shí),胰島素抵抗升高會(huì)破壞子宮內(nèi)環(huán)境,而這種子宮內(nèi)環(huán)境的改變與代謝、血管或炎癥失調(diào)有關(guān),其特征通常是輕度高血糖、血脂異常和炎癥增強(qiáng),特別是在妊娠晚期[15-16]。其中炎癥失調(diào)狀態(tài)可直接影響GDM患者的胎盤發(fā)育和功能,進(jìn)而影響胎兒,因此尋找可抑制GDM炎癥反應(yīng)的藥物將有助于抑制胰島素抵抗,從而保護(hù)母體和胎兒。
棕矢車菊素是一種生物活性黃酮,具有抗炎、抗氧化、抗菌、抗過敏和抗癌等多種藥理活性[17]。研究顯示,棕矢車菊素對(duì)糖尿病具有治療效果,可抑制高血糖小鼠血糖水平,降低胰島素抵抗[6]。因此,筆者預(yù)測(cè)棕矢車菊素可能具有防治GDM的作用。本研究結(jié)果證實(shí),棕矢車菊素抑制GDM大鼠空腹血糖,胰島素水平以及降低胰島素抵抗指數(shù),表明棕矢車菊素可有效改善GDM大鼠的糖代謝紊亂和胰島素抵抗。此外,GDM引起大鼠胎盤組織細(xì)胞凋亡增加,胎盤組織嚴(yán)重受損,而棕矢車菊素干預(yù)可減輕胎盤組織凋亡和損傷,表明棕矢車菊素對(duì)GDM具有保護(hù)作用。本研究結(jié)果顯示,棕矢車菊素可降低胎盤組織中炎性因子IL-1β、TNF-α水平,抑制GDM大鼠炎癥反應(yīng),證實(shí)了棕矢車菊素可降低GDM大鼠血糖,抑制炎癥反應(yīng)和細(xì)胞凋亡,減輕胎盤組織損傷,改善GDM大鼠的糖代謝紊亂和IR。
SDF-1α與CXCR4的特異性結(jié)合具有多種生物學(xué)效應(yīng)[18]。在穩(wěn)態(tài)條件下,SDF-1α及其同源受體CXCR4對(duì)于中性粒細(xì)胞和淋巴細(xì)胞的造血發(fā)育和歸巢至關(guān)重要。然而,在應(yīng)激條件下,損傷組織中SDF-1α/CXCR4信號(hào)傳導(dǎo)升高會(huì)促進(jìn)中性粒細(xì)胞從骨髓釋放到血液中,隨后循環(huán)中性粒細(xì)胞向損傷部位遷移和歸巢[19]。有研究顯示,抑制SDF-1α/CXCR4信號(hào)通路可抑制膝骨關(guān)節(jié)炎炎癥,從而改善關(guān)節(jié)炎,表明SDF-1α/CXCR4信號(hào)通路發(fā)揮促炎作用,抑制其通路可有效抑制過度炎癥反應(yīng)[20]。另有研究發(fā)現(xiàn),與正常妊娠孕婦相比,GDM孕婦血清中SDF-1α水平升高,SDF-1α是GDM發(fā)展的病理生理學(xué)的潛在靶標(biāo)[21-22]。本研究結(jié)果亦顯示GDM大鼠中SDF-1α/CXCR4通路被激活,而不同劑量棕矢車菊素干預(yù)后,大鼠胎盤組織中SDF-1α/CXCR4蛋白水平被顯著抑制,推測(cè)棕矢車菊素可能通過此通路保護(hù)GDM大鼠。為驗(yàn)證此猜想,本研究將SDF-1α/CXCR4激活劑和棕矢車菊素共同干預(yù)GDM大鼠,結(jié)果顯示SDF-1α/CXCR4通路被激活,棕矢車菊素對(duì)GDM大鼠的保護(hù)作用被部分抑制,提示棕矢車菊素對(duì)GDM大鼠炎癥反應(yīng)的抑制作用可能是通過抑制SDF-1α/CXCR4通路實(shí)現(xiàn)的。
綜上所述,棕矢車菊素可能通過抑制SDF-1α/CXCR4通路抑制GDM大鼠炎癥反應(yīng),從而減輕大鼠胰島素抵抗。本研究為GDM治療提供了新的參考,但是否存在其他通路發(fā)揮治療作用需進(jìn)一步研究。
參考文獻(xiàn)
[1] SWEETING A,WONG J,MURPHY H R,et al. A clinical update on gestational diabetes mellitus[J]. Endocr Rev,2022,43(5):763-793. doi:10.1210/endrev/bnac003.
[2] ZHANG J,CHI H,XIAO H,et al. Interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) single nucleotide polymorphisms (SNPs),inflammation and metabolism in gestational diabetes mellitus in inner mongolia[J]. Med Sci Monit,2017,23(1):4149-4157. doi:10.12659/msm.903565.
[3] CHEN X,WU J,F(xiàn)U X,et al. Fructus mori polysaccharide alleviates diabetic symptoms by regulating intestinal microbiota and intestinal barrier against TLR4/NF-κB pathway[J]. Int J Biol Macromol,2023,2023(1):126038-126049. doi:10.1016/j.ijbiomac.2023.126038.
[4] QIAO L,WATTEZ J S,LEE S,et al. Adiponectin deficiency impairs maternal metabolic adaptation to pregnancy in mice[J]. Diabetes,2017,66(5):1126-1135. doi:10.2337/db16-1096.
[5] 黃春薈,杜世拔,翟銳銳. 加味四妙丸介導(dǎo)SDF-1/CXCR4信號(hào)通路對(duì)痛風(fēng)性關(guān)節(jié)炎的治療作用[J]. 中國(guó)老年學(xué)雜志,2023,43(7):1707-1710. HUANG C H,DU S B,ZHAI R R. Therapeutic effect of modified Simiao Pill mediated SDF-1/CXCR4 signaling pathway on gouty arthritis[J]. Chinese Journal of Gerontology,2019,43(7):1707-1710. doi:10.3969/j.issn.1005-9202.2023.07.045.
[6] GLAWE J D,MIJALIS E M,DAVIS W C,et al. SDF-1-CXCR4 differentially regulates autoimmune diabetogenic T cell adhesion through ROBO1-SLIT2 interactions in mice[J]. Diabetologia,2013,56(10):2222-2230. doi:10.1007/s00125-013-2978-x.
[7] 王海艷,秦海霞,李淑娟. 棕矢車菊素誘導(dǎo)人宮頸癌Hela細(xì)胞G2/M期停滯的機(jī)制研究[J]. 現(xiàn)代腫瘤醫(yī)學(xué),2022,30(18):3264-3269. WANG H Y,QIN H X,LI S J. Study on mechanism of G_2/M phase stagnation induced by cyanidin in human Cervical cancer Hela cells[J]. Modern Oncology Medicine,2022,30(18):3264-3269. doi:10.3969/j.issn.1672-4992.2022.18.002.
[8] PARK E,HONG K,KWON B M,et al. Jaceosidin ameliorates insulin resistance and kidney dysfunction by enhancing insulin receptor signaling and the antioxidant defense system in type 2 diabetic mice[J]. J Med Food,2020,23(10):1083-1092. doi:10.1089/jmf.2020.4739.
[9] 曹小蝶,馬沖,陳立. 棕矢車菊素的藥理作用及其作用機(jī)制的研究進(jìn)展[J]. 現(xiàn)代藥物與臨床,2022,37(11):2653-2658. CAO X D,MA C,CHEN L. Research progress on the pharmacological action and mechanism of cyanidin[J]. Modern Medicine and Clinic,2022,37(11):2653-2658.
[10] 陳蓓,連李斌. 丹皮酚抑制Notch1/Jagged1信號(hào)通路對(duì)妊娠糖尿病大鼠糖代謝紊亂的改善作用[J]. 河北醫(yī)藥,2023,45(11):1632-1636. CHEN B,LIAN L B. Effects of paeonol inhibition of Notch1/Jagged1 signaling pathway on glucose metabolism disorder in gestational diabetes mellitus rats[J]. Journal of Hebei Medicine,2023,45(11):1632-1636. doi:10.3969/j.issn.1002-7386.2023.11.006.
[11] OUYANG Z,LI W,MENG Q,et al. A natural compound jaceosidin ameliorates endoplasmic reticulum stress and insulin resistance via upregulation of SERCA2b[J]. Biomed Pharmacother,2017,89(1):1286-1296. doi:10.1016/j.biopha.2017.03.023.
[12] 潘蕓,楊陽(yáng),劉甜,等. 大黃素調(diào)節(jié)SDF-1α/CXCR4軸抑制模型大鼠增生性瘢痕的作用[J]. 中國(guó)皮膚性病學(xué)雜志,2023,37(11):1237-1245. PAN Y,YANG Y,LIU T,et al. Emodin modulates SDF-1α/CXCR4 axis to inhibit hypertrophic scar in model rats[J]. Chinese Journal of Dermatology and Venereology,2023,37(11):1237-1245. doi:10.13735/j.cjdv.1001-7089.202303148.
[13] CHOUDHURY A A,DEVI RAJESWARI V. Gestational diabetes mellitus - A metabolic and reproductive disorder[J]. Biomed Pharmacother,2021,143(1):112183-112196. doi:10.1016/j.biopha.2021.112183.
[14] VISIEDO F,VáZQUEZ-FONSECA L,áBALOS-MARTíNEZ J,et al. Maternal elevated inflammation impairs placental fatty acids β- oxidation in women with gestational diabetes mellitus[J]. Front Endocrinol(Lausanne),2023,14(1):1146574-1146585. doi:10.3389/fendo.2023.1146574.
[15] LIZáRRAGA D,GARCíA-GASCA A. The placenta as a target of epigenetic alterations in women with gestational diabetes mellitus and potential implications for the offspring[J]. Epigenomes,2021,5(2):13-22. doi:10.3390/epigenomes5020013.
[16] 田亞靜,楊雪,汪靜,等. 芒柄花素對(duì)妊娠期糖尿病大鼠氧化應(yīng)激損傷的影響[J]. 天津醫(yī)藥,2023,51(7):734-738.TIAN Y J,YANG X,WANG J,et al. Influence of formononetin on oxidative stress injury in gestational diabetes mellitus rats[J]. Tianjin Med J,2023,51(7):734-738. doi: 10.11958/20221450.
[17] NAGEEN B,RASUL A,HUSSAIN G,et al. Jaceosidin:a natural flavone with versatile pharmacological and biological activities[J]. Curr Pharm Des,2021,27(4):456-466. doi:10.2174/1381612826666200429095101.
[18] CHEN J,CHEN N,ZHANG T,et al. Rongjin Niantong Fang ameliorates cartilage degeneration by regulating the SDF-1/CXCR4-p38MAPK signalling pathway[J]. Pharm Biol,2022,60(1):2253-2265. doi:10.1080/13880209.2022.2143533.
[19] CHATTERJEE T,LEWIS T L,ARORA I,et al. Sex-based disparities in leukocyte migration and activation in response to inhalation lung injury:Role of SDF-1/CXCR4 signaling[J]. Cells,2023,12(13):1719-1730. doi:10.3390/cells12131719.
[20] 王雷,余德濤,邢禎全. 依托考昔抑制SDF-1/CXCR4信號(hào)通路影響骨關(guān)節(jié)炎軟骨細(xì)胞增殖、凋亡及炎性因子表達(dá)[J]. 現(xiàn)代免疫學(xué),2021,41(6):468-472. WANG L,YU D T,XING Z Q. Etocoxib inhibits SDF-1/CXCR4 signaling pathway and Influences proliferation,apoptosis and expression of inflammatory factors of chondrocytes in osteoarthritis[J]. Modern Immunology,2021,41(6):468-472.
[21] DARAKHSHAN S,F(xiàn)ATEHI A,HASSANSHAHI G,et al. Serum concentration of angiogenic(CXCL1,CXCL12) and angiostasis (CXCL9,CXCL10) CXC chemokines are differentially altered in normal and gestational diabetes mellitus associated pregnancies[J]. J Diabetes Metab Disord,2019,18(2):371-378. doi:10.1007/s40200-019-00421-2.
[22] LIU H,LIU A,KAMINGA A C,et al. Chemokines in gestational diabetes mellitus[J]. Front Immunol,2022,13:705852. doi:10.3389/fimmu.2022.705852.
(2023-08-11收稿 2023-10-24修回)
(本文編輯 陸榮展)